Figure 6

TGFB1 expression predicts responses to immunotherapy (A) Violin plots comparing TGFB1 expression between patients who benefit and who do not benefit from immunotherapy in AML, as predicted by the TIDE algorithm. (B) Bar plots showing percentages of responders (complete response [CR] or partial response [PR]) and non-responders (stable disease [SD] or progressive disease [PD]) to ICB among indicated ICB cohorts between patients with high and low TGFB1 expression (as stratified by the median expression value). (C) Violin plots comparing TGFB1 expression in responders (complete response [CR] or partial response [PR]) and non-responders (stable disease [SD] or progressive disease [PD]). (D) Kaplan–Meier curves depicting the OS and PFS of ICB-treated patients with high and low TGFB1 expression. The optimal cut-off of TGFB1 was determined by the Maxstat method. In (B–D), each vertical column corresponds to one ICB cohort as indicated in (B).